Erschienen in:
14.01.2019 | Review Article
Time for radioimmunotherapy: an overview to bring improvements in clinical practice
verfasst von:
O. Leaman Alcibar, D. Candini, F. López-Campos, M. Albert Antequera, V. Morillo Macías, A. J. Conde, A. Rodríguez Pérez, A. Hervás Morón, J. Contreras Martínez, C. Ferrer Albiach, S. Navarro Aguilar, M. E. Rodríguez-Ruiz
Erschienen in:
Clinical and Translational Oncology
|
Ausgabe 8/2019
Einloggen, um Zugang zu erhalten
Abstract
Harnessing the patient’s own immune system against an established cancer has proven to be a successful strategy. Within the last years, several antibodies blocking critical “checkpoints” that control the activation of T cells, the immune cells able to kill cancer cells, have been approved for the use in patients with different tumours. Unfortunately, these cases remain a minority. Over the last years, radiotherapy has been reported as a means to turn a patient’s own tumour into an in situ vaccine and generate anti-tumour T cells in patients who lack sufficient anti-tumour immunity. Indeed, review data show that the strategy of blocking multiple selected immune inhibitory targets in combination with radiotherapy has the potential to unleash powerful anti-tumour responses and improve the outcome of metastatic solid tumours. Here, we review the principal tumours where research in this field has led to new knowledge and where radioimmunotherapy becomes a reality.